GB1430942A - 21-substituted 3alpha-hydroxy pregnanes - Google Patents

21-substituted 3alpha-hydroxy pregnanes

Info

Publication number
GB1430942A
GB1430942A GB2114272A GB2114272A GB1430942A GB 1430942 A GB1430942 A GB 1430942A GB 2114272 A GB2114272 A GB 2114272A GB 2114272 A GB2114272 A GB 2114272A GB 1430942 A GB1430942 A GB 1430942A
Authority
GB
United Kingdom
Prior art keywords
alpha
substituted
3alpha
hydroxy
additionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2114272A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Priority to GB2114272A priority Critical patent/GB1430942A/en
Priority to DE2322532A priority patent/DE2322532A1/de
Priority to IE709/73A priority patent/IE37596B1/xx
Priority to CH636073A priority patent/CH617710A5/de
Priority to AT395173A priority patent/AT355232B/de
Priority to ZA733035A priority patent/ZA733035B/xx
Priority to ES0414411A priority patent/ES414411A1/es
Priority to SE7306330A priority patent/SE400771B/xx
Priority to CA170,482A priority patent/CA1013341A/en
Priority to JP48050183A priority patent/JPS4961150A/ja
Priority to IL42196A priority patent/IL42196A/xx
Priority to NL7306234A priority patent/NL7306234A/xx
Priority to FR7316108A priority patent/FR2183792B1/fr
Priority to AU55284/73A priority patent/AU475168B2/en
Priority to LU67546A priority patent/LU67546A1/xx
Priority to BE130749A priority patent/BE799102A/xx
Publication of GB1430942A publication Critical patent/GB1430942A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
GB2114272A 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes Expired GB1430942A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes
DE2322532A DE2322532A1 (de) 1972-05-05 1973-05-04 Pregnanderivate und verfahren zu ihrer herstellung
IE709/73A IE37596B1 (en) 1972-05-05 1973-05-04 21-substituted 3alpha-hydroxy pregnanes
CH636073A CH617710A5 (en) 1972-05-05 1973-05-04 Process for the preparation of steroids of the pregnane or 19-norpregnane series with anaesthetic activity
AT395173A AT355232B (de) 1972-05-05 1973-05-04 Verfahren zur herstellung von neuen steroiden der pregnan- oder 19-norpregnanreihe
ZA733035A ZA733035B (en) 1972-05-05 1973-05-04 Compounds of the pregnane series having anaesthetic activity
ES0414411A ES414411A1 (es) 1972-05-05 1973-05-04 Procedimiento para la preparacion de esteroides de las series del pregnano o del 19-norpregnano.
SE7306330A SE400771B (sv) 1972-05-05 1973-05-04 Forfarande for framstellning av 3alfa-hydroxi- och 3alfa-hydroxi-19-norpregnaner
CA170,482A CA1013341A (en) 1972-05-05 1973-05-04 Compound of the pregnane series having anaesthetic activity
JP48050183A JPS4961150A (enrdf_load_stackoverflow) 1972-05-05 1973-05-04
IL42196A IL42196A (en) 1972-05-05 1973-05-04 Anaesthetic steroids of the pregnane or norpregnane series
NL7306234A NL7306234A (enrdf_load_stackoverflow) 1972-05-05 1973-05-04
FR7316108A FR2183792B1 (enrdf_load_stackoverflow) 1972-05-05 1973-05-04
AU55284/73A AU475168B2 (en) 1972-05-05 1973-05-04 Anaesthetic pregnanes
LU67546A LU67546A1 (enrdf_load_stackoverflow) 1972-05-05 1973-05-04
BE130749A BE799102A (fr) 1972-05-05 1973-05-04 Composes anesthesiques de la serie du pregnane et compositions en contenant,

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Publications (1)

Publication Number Publication Date
GB1430942A true GB1430942A (en) 1976-04-07

Family

ID=10157915

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2114272A Expired GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Country Status (16)

Country Link
JP (1) JPS4961150A (enrdf_load_stackoverflow)
AT (1) AT355232B (enrdf_load_stackoverflow)
AU (1) AU475168B2 (enrdf_load_stackoverflow)
BE (1) BE799102A (enrdf_load_stackoverflow)
CA (1) CA1013341A (enrdf_load_stackoverflow)
CH (1) CH617710A5 (enrdf_load_stackoverflow)
DE (1) DE2322532A1 (enrdf_load_stackoverflow)
ES (1) ES414411A1 (enrdf_load_stackoverflow)
FR (1) FR2183792B1 (enrdf_load_stackoverflow)
GB (1) GB1430942A (enrdf_load_stackoverflow)
IE (1) IE37596B1 (enrdf_load_stackoverflow)
IL (1) IL42196A (enrdf_load_stackoverflow)
LU (1) LU67546A1 (enrdf_load_stackoverflow)
NL (1) NL7306234A (enrdf_load_stackoverflow)
SE (1) SE400771B (enrdf_load_stackoverflow)
ZA (1) ZA733035B (enrdf_load_stackoverflow)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752860A4 (en) * 1994-02-14 1998-05-06 Cocensys Inc ANDROSTANE AND PREGNANE FOR ALLOSTERIC MODULATION OF THE GABA RECEPTOR
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
US9365611B2 (en) 2013-04-17 2016-06-14 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10023606B2 (en) 2013-04-17 2018-07-17 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
JP4915427B2 (ja) * 2009-03-30 2012-04-11 ブラザー工業株式会社 液体供給ジョイント、これを使用した液体吐出ヘッド及び記録装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1346292A (fr) * 1962-09-14 1963-12-20 Roussel Uclaf Nouveau procédé de préparation des 21-amino stéroïdes
US3144446A (en) * 1963-12-20 1964-08-11 Upjohn Co Mono and bis nu-(3alpha, 17alpha-dihydroxy-11, 20-dioxo-5beta-pregnan-21-yl) quaternary ammonium salts of triethylenediamine

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US6143736A (en) * 1994-02-14 2000-11-07 Cocensys, Inc. Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US6277838B1 (en) 1994-02-14 2001-08-21 Cocensys, Inc. Methods for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP1038880A3 (en) * 1994-02-14 2003-07-16 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of GABA receptor
EP0752860A4 (en) * 1994-02-14 1998-05-06 Cocensys Inc ANDROSTANE AND PREGNANE FOR ALLOSTERIC MODULATION OF THE GABA RECEPTOR
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
WO2002053577A3 (en) * 2000-12-29 2002-10-10 Elpen S A Gabaa modulating neurosteroids
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US12201640B2 (en) 2013-04-17 2025-01-21 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof
US10342810B2 (en) 2013-04-17 2019-07-09 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9365611B2 (en) 2013-04-17 2016-06-14 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10023606B2 (en) 2013-04-17 2018-07-17 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11912737B2 (en) 2013-04-17 2024-02-27 Sage Therpeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12071453B2 (en) 2013-08-23 2024-08-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12065463B2 (en) 2014-10-16 2024-08-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12180248B2 (en) 2014-10-16 2024-12-31 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11554125B2 (en) 2016-03-08 2023-01-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Also Published As

Publication number Publication date
ES414411A1 (es) 1976-02-01
JPS4961150A (enrdf_load_stackoverflow) 1974-06-13
SE400771B (sv) 1978-04-10
CA1013341A (en) 1977-07-05
FR2183792B1 (enrdf_load_stackoverflow) 1977-07-15
LU67546A1 (enrdf_load_stackoverflow) 1973-07-13
AT355232B (de) 1980-02-25
CH617710A5 (en) 1980-06-13
NL7306234A (enrdf_load_stackoverflow) 1973-11-07
ATA395173A (de) 1979-07-15
FR2183792A1 (enrdf_load_stackoverflow) 1973-12-21
IE37596B1 (en) 1977-08-31
BE799102A (fr) 1973-11-05
IE37596L (en) 1973-11-05
DE2322532A1 (de) 1973-11-22
IL42196A (en) 1978-10-31
AU5528473A (en) 1974-11-07
IL42196A0 (en) 1973-07-30
ZA733035B (en) 1974-04-24
AU475168B2 (en) 1976-08-12

Similar Documents

Publication Publication Date Title
GB1430942A (en) 21-substituted 3alpha-hydroxy pregnanes
NZ182836A (en) 9 ,21-dihalo-6 -fluoro-11 ,17 -dihydroxy 16 -methyl-pregna-1,4-diene-3,20-diones
US3094198A (en) Structural panel
CH533736A (de) Zwischen zwei Bauteilen angebrachtes Lager sowie Verfahren zu dessen Herstellung
CA1016535A (en) .delta. 8,9 steroids of the pregnane series
SE317968B (enrdf_load_stackoverflow)
GB1033240A (en) Tantalum base alloys
AU3998072A (en) 16, 17-cyclopropa steroids ofthe androstane series
CA815065A (en) N-PROPYL-13.beta. BIS NOR-18,19 SECO-4,5 PREGNANE, PREGNENE ET PREGNADIENE
IE37597L (en) 21-fluoro pregnanes.
GB1008273A (enrdf_load_stackoverflow)
BERTRAND et al. The study of the reactions C 12 plus t at energies between 0. 5 and 1. 2 MeV(Angular distributions and absolute cross sections for C-12 triton reactions at triton energies between 0. 5 and 1. 0 MeV, and excitation curves)
NZ182865A (en) 2.9 -dichloro-6 -fluoro-16 -methyl-11 ,17 , 21-trihydroxy-pregna-1,4-diene-3,20-diones
ES354795A1 (es) Procedimiento de preparacion de nuevos 4,6-dicloro-delta4,6-esteroides de la serie pregnano y androstano.
CA700410A (en) METHOD OF PREPARING SUBSTITUTED 21-SULFONYLOXY-16.alpha.,17.alpha.-DIHYDROXY STEROIDS OF THE PREGNANE SERIES
CA859136A (en) 16-ALKYL-11-OXYGENATED-4-PREGNENE-17.alpha.-OL-3,20-DIONE AND THE CORRESPONDING 1,4-PREGNADIENE COMPOUNDS
CA972350A (en) 1,2-METHYLENE-17.alpha.-ACYLOXY(OR IMPROVED HYDROXY)-9.beta.,10.alpha.-STEROID COMPOUNDS OF THE PREGNANE SERIES, PHARMACEUTIC PREPARATIONS OF THE BASIS OF THE NOVEL COMPOUNDS AND METHODS OF PRODUCING SAID COMPOUNDS AND PREPARATIONS
GB1131445A (en) Novel steroids
CA737447A (en) 3,6,20-TRIOXO A-NOR B-HOMO 10 .epsilon. 19-NOR PREGNANE
FR2031806A5 (en) 17beta-spiro-oxiranes of the oestrane series
AU4229764A (en) 3' - oxo - 4' - hydroxy - cyclopenteno - ( 1'-2' 16,17 ) - steroids of the androstane series
ES386181A2 (es) Procedimiento para la preparacion de eteres diglicidilicos.
FR2274308A1 (fr) Nouveaux derives du 19-nor pregnane, leur procede de preparation et leur application comme medicament
CA696622A (en) 2,4-DIBROMO 17.alpha.-HYDROXY 21-ACETOXY PREGNANE 3,20 DIONE
CA858631A (en) Hardenable compositions based on triglycidyl isocyanurate

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee